Bristol-Myers Squibb Co at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Transcript
Okay, great. Well, thanks for joining us, everybody. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs, and we're very pleased to have Bristol-Myers Squibb with us this morning.
From the company, we have Giovanni Caforio, who is Chairman and CEO. Giovanni, thank you very much for being here this morning, really appreciate the time.
Thank you, Terence. Thanks. Good morning, everyone.
Questions & Answers
So maybe to kick off, as everyone knows, this is about the 1-year anniversary of when you announced the Celgene deal. Would love for you to maybe recap the progress that's been made here since the announcement. And looking ahead, what are really the key drivers that we should all be focused on as we think about you guys generating a return from the acquisition?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
